Logo image of ABP

ABPRO HOLDINGS INC (ABP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ABP - US0008471031 - Common Stock

7.04 USD
+0.67 (+10.52%)
Last: 11/21/2025, 8:10:44 PM
7.04 USD
0 (0%)
After Hours: 11/21/2025, 8:10:44 PM
Fundamental Rating

0

ABP gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 535 industry peers in the Biotechnology industry. ABP has a bad profitability rating. Also its financial health evaluation is rather negative. ABP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ABP has reported negative net income.
ABP had a negative operating cash flow in the past year.
ABP Yearly Net Income VS EBIT VS OCF VS FCFABP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

ABP has a worse Return On Assets (-396.00%) than 95.14% of its industry peers.
Industry RankSector Rank
ROA -396%
ROE N/A
ROIC N/A
ROA(3y)-240.71%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ABP Yearly ROA, ROE, ROICABP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ABP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABP Yearly Profit, Operating, Gross MarginsABP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

ABP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABP has been increased compared to 1 year ago.
ABP has a worse debt/assets ratio than last year.
ABP Yearly Shares OutstandingABP Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 500K 1M 1.5M
ABP Yearly Total Debt VS Total AssetsABP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

ABP has an Altman-Z score of -29.94. This is a bad value and indicates that ABP is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -29.94, ABP is doing worse than 88.60% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -29.94
ROIC/WACCN/A
WACC8.66%
ABP Yearly LT Debt VS Equity VS FCFABP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

ABP has a Current Ratio of 0.19. This is a bad value and indicates that ABP is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.19, ABP is not doing good in the industry: 95.51% of the companies in the same industry are doing better.
A Quick Ratio of 0.19 indicates that ABP may have some problems paying its short term obligations.
ABP has a Quick ratio of 0.19. This is amonst the worse of the industry: ABP underperforms 95.14% of its industry peers.
Industry RankSector Rank
Current Ratio 0.19
Quick Ratio 0.19
ABP Yearly Current Assets VS Current LiabilitesABP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

ABP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -955.41%.
Looking at the last year, ABP shows a very strong growth in Revenue. The Revenue has grown by 289.36%.
EPS 1Y (TTM)-955.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-780.03%
Revenue 1Y (TTM)289.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, ABP will show a very negative growth in Earnings Per Share. The EPS will decrease by -28.56% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.25%
EPS Next 2Y-19.9%
EPS Next 3Y-28.56%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ABP Yearly Revenue VS EstimatesABP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 50K 100K 150K
ABP Yearly EPS VS EstimatesABP Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 -0.1 -0.2 -0.3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ABP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ABP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABP Price Earnings VS Forward Price EarningsABP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABP Per share dataABP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

A cheap valuation may be justified as ABP's earnings are expected to decrease with -28.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.9%
EPS Next 3Y-28.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ABP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABPRO HOLDINGS INC

NASDAQ:ABP (11/21/2025, 8:10:44 PM)

After market: 7.04 0 (0%)

7.04

+0.67 (+10.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)N/A N/A
Inst Owners7.1%
Inst Owner Change-85.09%
Ins Owners3.06%
Ins Owner Change2.25%
Market Cap564.40M
Revenue(TTM)183.00K
Net Income(TTM)-18.46M
Analysts45
Price TargetN/A
Short Float %N/A
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2900%
EPS NQ rev (3m)-2900%
EPS NY rev (1m)-31.25%
EPS NY rev (3m)-31.25%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3084.14
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-22.9
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS0
BVpS-0.19
TBVpS-0.2
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -396%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-240.71%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.19
Quick Ratio 0.19
Altman-Z -29.94
F-Score4
WACC8.66%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-955.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-780.03%
EPS Next Y-31.25%
EPS Next 2Y-19.9%
EPS Next 3Y-28.56%
EPS Next 5YN/A
Revenue 1Y (TTM)289.36%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-117.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-21.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-21.99%
OCF growth 3YN/A
OCF growth 5YN/A

ABPRO HOLDINGS INC / ABP FAQ

What is the fundamental rating for ABP stock?

ChartMill assigns a fundamental rating of 0 / 10 to ABP.


What is the valuation status for ABP stock?

ChartMill assigns a valuation rating of 0 / 10 to ABPRO HOLDINGS INC (ABP). This can be considered as Overvalued.


How profitable is ABPRO HOLDINGS INC (ABP) stock?

ABPRO HOLDINGS INC (ABP) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for ABP stock?

The Earnings per Share (EPS) of ABPRO HOLDINGS INC (ABP) is expected to decline by -31.25% in the next year.